Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
H Li, P Er Saw, E Song - Cellular & molecular immunology, 2020 - nature.com
Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …
Targeting immunogenic cell stress and death for cancer therapy
Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific
stressors, occupies a central position in the development of novel anticancer treatments …
stressors, occupies a central position in the development of novel anticancer treatments …
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are
aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic …
aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic …
Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer
NE Annels, D Mansfield, M Arif… - Clinical Cancer …, 2019 - AACR
Abstract Purpose: The CANON [CA VATAK in NON–muscle-invasive bladder cancer
(NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 …
(NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 …
Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile
L Guo, C Hu, Y Liu, X Chen, D Song, R Shen… - Nature …, 2023 - nature.com
Oncolytic viruses (OVs) represent a type of encouraging multi-mechanistic drug for the
treatment of cancer. However, attenuation of virulence, which is generally required for the …
treatment of cancer. However, attenuation of virulence, which is generally required for the …
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing
progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group …
progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group …
[HTML][HTML] Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
M Li, M Zhang, Q Ye, Y Liu, W Qian - Cancer biology & medicine, 2023 - ncbi.nlm.nih.gov
Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an
ability to elicit curative effects via systemic administration. Tumor cells often create an …
ability to elicit curative effects via systemic administration. Tumor cells often create an …
Oncolytic herpes simplex virus-based therapies for cancer
With the increased worldwide burden of cancer, including aggressive and resistant cancers,
oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex …
oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex …
Immune microenvironment and immunotherapies for diffuse intrinsic pontine glioma
Y Chen, C Zhao, S Li, J Wang, H Zhang - Cancers, 2023 - mdpi.com
Simple Summary Diffuse intrinsic pontine glioma (DIPG) is a malignant primary glial tumor
that occurs in all age groups but predominates in children and is estimated to account for …
that occurs in all age groups but predominates in children and is estimated to account for …
Development of oncolytic virotherapy: From genetic modification to combination therapy
Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically
modified viruses to selectively replicate in and kill malignant cells. Many genetically modified …
modified viruses to selectively replicate in and kill malignant cells. Many genetically modified …